바이오에이지 랩스 (BIOA) 주가

바이오에이지 랩스(BIOA)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - Specialty & Generic 기업입니다. 현재가 $8.01 (-0.99%), 시가총액 $0.79B, 52주 최저~최고 $3.90 ~ $22.92.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company

핵심 지표

• 현재가: $8.01 (-0.99%)
• 시가총액: $0.79B
• 52주 최저~최고: $3.90 ~ $22.92
• 섹터: Healthcare
• 산업: Drug Manufacturers - Specialty & Generic
• 거래소: NASDAQ

바이오에이지 랩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

바이오에이지 랩스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 2.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.11
• 순이익률: 0.00%
• 영업이익률: -9.15%

자주 묻는 질문